Related Experiment Video
Updated: May 28, 2026
08:40
Light-driven Molecular Motors on Surfaces for Single Molecular Imaging
Published on: March 13, 2019
Unlocking a modular Gd-DOTBA platform via tetramaleimide click chemistry for high-performance MRI
Xinhui Xiao1,2, Shiyao Wang1, Peijie Guan1,2
1Department of Radiology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, China. cn_boy2000@wmu.edu.cn.
Chemical Communications (Cambridge, England)
|May 27, 2026
Summary
A new modular platform for MRI probes, Gd-DOTBA-Mal, allows precise bioconjugation. This enhances MRI sensitivity for kidney and tumor imaging, potentially reducing required doses.
Area of Science:
- Biomedical Engineering
- Radiochemistry
- Molecular Imaging
Background:
- Gadolinium-based contrast agents (GBCAs) are crucial for MRI.
- Developing GBCAs with improved relaxivity and stability is an ongoing challenge.
- Site-specific conjugation is key for targeted molecular MRI probes.
Purpose of the Study:
- To develop a versatile, modular scaffold for high-performance MRI probes.
- To enable site-specific bioconjugation for advanced molecular imaging applications.
- To assess the performance of a novel Gd-DOTBA-Mal conjugate for in vivo imaging.
Main Methods:
- Synthesis of a tetramaleimide-functionalized Gd-DOTBA scaffold (Gd-DOTBA-Mal).
- Site-specific conjugation of the scaffold to cysteine via maleimide chemistry.
- Evaluation of the conjugate's relaxivity, stability, and performance in preclinical kidney dysfunction and tumor imaging models.
Main Results:
- The Gd-DOTBA-Mal scaffold provides a modular platform for probe development.
- The cysteine conjugate demonstrated high relaxivity and excellent stability.
- Successful in vivo imaging of kidney dysfunction and tumors was achieved at reduced doses.
Conclusions:
- The Gd-DOTBA-Mal platform enables the creation of advanced, high-performance MRI probes.
- Site-specific bioconjugation leads to enhanced imaging sensitivity and stability.
- This approach facilitates the development of novel molecular imaging agents for clinical applications.
